A Phase III, Randomized, Double-Blind Trial of TMC278 [rilpivirine] 25mg q.d. Versus Efavirenz 600mg q.d. in Combination With a Fixed Background Regimen Consisting of Tenofovir Disoproxil Fumarate and Emtricitabine in Antiretroviral-Naive HIV-1 Infected Subjects.

Trial Profile

A Phase III, Randomized, Double-Blind Trial of TMC278 [rilpivirine] 25mg q.d. Versus Efavirenz 600mg q.d. in Combination With a Fixed Background Regimen Consisting of Tenofovir Disoproxil Fumarate and Emtricitabine in Antiretroviral-Naive HIV-1 Infected Subjects.

Completed
Phase of Trial: Phase III

Latest Information Update: 12 Feb 2016

At a glance

  • Drugs Rilpivirine (Primary) ; Efavirenz; Emtricitabine/tenofovir disoproxil fumarate
  • Indications HIV-1 infections
  • Focus Pharmacogenomic; Registrational; Therapeutic Use
  • Acronyms ECHO; SPRINT
  • Sponsors Janssen R&D Ireland
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 01 Apr 2014 96- Week results from a pooled analysis of ECHO and THRIVE published in the Clinical Infectious Diseases.
    • 16 Jan 2014 Results assessing effect of treatment on 25-hydroxyvitamin D levels published in the Antiviral Therapy.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top